PAION AG operates as a pharmaceutical company, which engages in the development of drugs to be used in out-patient and hospital-based sedation, anesthesia, and critical care services. The company is headquartered in Aachen, Nordrhein-Westfalen and currently employs 64 full-time employees. The company went IPO on 2005-02-11. The firm's main product is remimazolam, an intravenous ultra-short-acting benzodiazepine sedative and anesthetic. In the human body, remimazolam is metabolized to an inactive metabolite by tissue esterase and not metabolized by cytochrome-dependent hepatic pathways. In addition to that, remimazolam, which is in Phase III clinical development, can be reversed with flumazenil to terminate sedation and anesthesia, if necessary. The product can be used for general anesthesia in Europe and procedural sedation in the United States. The firm operates sites in Aachen, Germany, Cambridge, the United Kingdom, and New Jersey, the United States.
Follow-Up Questions
Who is the CEO of Paion AG?
Mr. Gregor Siebert is the Chairman of the Management Board of Paion AG, joining the firm since 2022.
What is the price performance of PAIOF stock?
The current price of PAIOF is $0, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Paion AG?
Paion AG belongs to Biotechnology industry and the sector is Health Care
What is Paion AG market cap?
Paion AG's current market cap is $0
Is Paion AG a buy, sell, or hold?
According to wall street analysts, 7 analysts have made analyst ratings for Paion AG, including 3 strong buy, 5 buy, 1 hold, 0 sell, and 3 strong sell
